Merck & Co sells ophthalmic brands and Colorado biologicals unit
US pharma giant Merck & Co (NYSE: MRK) has entered into two more divestment transactions, following the recent sell-off of its consumer business to Bayer for $14.2 billion (The Pharma Letter May 6), the firm is divesting a number of ophthalmic brands to Japan’s Santen Pharmaceuticals (TYO: 4536) in certain regions, and will also sell its Colorado-based biologicals manufacturing facility to KBI Biopharma.
The sales territories are Japan, Europe, and Asia Pacific, and annual sales in these markets associated with these ophthalmic products are around $400 million and include brands such as Cosopt (dorzolamide) and Timoptic (timolol maleate). Merck divested its US ophthalmology business to Akorn Pharmaceuticals in 2013 and 2014. It will continue to sell its eye products in Latin America, Canada, Australia, the Middle East, Africa and other markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze